Nycomed can draw on a tradition of quality and innovation that goes back to 1874 in Norway. The company has grown rapidly in recent years both in terms of the number of employees and new products.
Our history at a glance
| Year |
Event |
| 2011 |
Takeda to acquire Nycomed |
| 2011 |
FDA granted approval for roflumilast in the United States where it will be marketed under the brand name Daliresp™ |
| 2010 |
Acquisition of a majority stake in Guangdong Techpool Bio-Pharma |
|
| 2010 |
Daxas® approved in Europe |
| 2009 |
Instanyl® and Pantozol Control® launched |
| 2008 |
Acquisition of Bradley |
| 2007 |
Acquisition of Altana Pharma |
| 2006 |
Preotact® launched (osteoporosis) |
| 2005 |
Consortium led by Nordic Capital acquires majority stake in Nycomed; Alvesco® launched (asthma) |
| 2004 |
TachoSil® launched (tissue management) |
| 2002 |
Nycomed sold to CSFB, Blackstone and NIB Capital |
| 2000 |
Joint Venture Leiras, Finland (fully acquired in 2003) |
| 1999 |
Nordic Capital acquires Nycomed Pharma from Amersham |
| 1997 |
Merger with Amersham |
| 1994 |
Pantoprazole launched* (gastro-intestinal) |
| 1976 |
Ebrantil patented*(high blood pressure) |
| 1938 |
Optojod launched (contrast medium) |
| 1907 |
Euphyllin patented* (respiratory diseases) |
| 1874 |
Foundation of Nyegaard & Co (NYCO) |
*Altana Pharma